Additive and antagonist effects of therapeutic gene combinations for suppression of HIV-1 infection

Antiviral Research

Volumn 55, Issue 1, 2002, Pages 77-90

  Gennari, Francesca ^a   Biasolo, Maria Angela ^a   Cancellotti, Enrico ^a   Radaelli, Antonia ^b   De Giuli Morghen, Carlo ^b   Bozzoni, Irene ^c   Cereda, Paolo Martino ^d   Mengoli, Carlo ^a   Palù, Giorgio ^a   Parolin, Cristina ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

Adoptive cell therapy; Antisense tRNA; HIV 1 infection; Poly gene therapy; VAI ribozyme

Indexed keywords

COMPLEMENTARY RNA; RETROVIRUS VECTOR; HAMMERHEAD RIBOZYME; RIBOZYME; RIBOZYME UV5; TRANSACTIVATOR PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; GENE INSERTION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA CELL LINE; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; STOICHIOMETRY; VIRAL GENE THERAPY; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION; ADENOVIRUS; CHEMISTRY; COMPARATIVE STUDY; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; PHYSIOLOGY; RETROVIRUS; STATISTICS;

ADENOVIRIDAE; COMPARATIVE STUDY; GENE PRODUCTS, TAT; GENE THERAPY; GENETIC VECTORS; HIV-1; HUMAN; JURKAT CELLS; RETROVIRIDAE; RNA, ANTISENSE; RNA, CATALYTIC; STATISTICS; SUPPORT, NON-U.S. GOV'T; TRANSFECTION; VIRUS REPLICATION; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035997931     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00009-8     Document Type: Article

References (38)

1. Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines
2. A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection
3. TAR RNA decoys inhibit tat-activated HIV-1 transcription after preinitiation complex formation
4. Protection of primary humanT-cells from HIV infection by Trev: A transdominant fusion gene
5. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication
6. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy
7. +T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
8. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector
9. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades
10. Toward HIV eradication or remission: The tasks ahead
11. Serologic diagnosis and immunologic detection of virus infection
12. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy
13. Adenovirus VAI RNA antagonizes the antiviral action of the interferon-induced eIF-2 alpha kinase
14. Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single chain antibody against viral integrase
15. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17
16. Combination gene therapy: Synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule
17. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA
18. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS
19. Rational reconstitution of the immune repertoire in AIDS with autologous, antigen-specific, in vitro-expanded CD4 lymphocytes
20. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins
21. A mechanism for the control of protein synthesis by adenovirus VA RNAI
22. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector
23. Enhancement or inhibition of HIV-1 replication by intracellular expression of sense or antisense RNA targeted at different intermediates of reverse transcription
24. Interference between effector RNAs expressed from conventional dual-function anti-HIV retroviral vectors can be circumvented using dual-effector-cassette retroviral vectors
25. Use of adenoviral VAI small RNA as a carrier for cytoplasmic delivery of ribozymes
26. Genetic variation in a human immunodeficiency virus type 2 live-virus Macaca nemestrina vaccine model
27. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
28. Complete nucleotide sequence of the AIDS virus, HTLVIII
29. Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line
30. Ribozymes as anti-HIV-1 therapeutic agents: Principles, applications and problems
31. Analysis of intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells
32. + lymphocytes
33. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication
34. Quantitative evaluation of intracellular sense: Antisense RNA hybrid duplexes
35. Preclinical characterization of an anti-tat ribozyme for therapeutic application
36. Phenotypic knock out of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection
37. Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry
38. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy